Top 3 Health Care Stocks That May Explode In Q3
Top 3 Health Care Stocks That May Explode In Q3
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
醫療保健板塊中最超賣的股票提供了買入低估公司的機會。`
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
RSI指標是一種動量指標，它比較了股票在價格上漲時的強度與在價格下跌時的強度。與股票的價格走勢進行比較，可以給交易者更好的了解股票短期內表現的良好程度。當RSI低於30時，資產通常被認爲是超賣的，根據Benzinga Pro的數據。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是本行業板塊最近的主要超賣股票列表，RSI接近或低於30。
Edwards Lifesciences Corp (NYSE:EW)
愛德華生命科學公司（紐交所：EW）
- On July 24, Edwards Lifesciences reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix. The company's stock fell around 27% over the past five days and has a 52-week low of $58.93 .
- RSI Value: 24.03
- EW Price Action: Shares of Edwards Lifesciences fell 0.2% to close at $63.64 on Tuesday.
- Benzinga Pro's real-time newsfeed alerted to latest EW news.
- 愛德華生命科學於7月24日公佈了次季度營收低於預期及第三季度的預測指導不及預估。此外，公司還收購了JenaValve和Endotronix公司。公司的股票在過去5天下跌了近27%，並創下了52周內的最低價$ 58.93。
- RSI值：24.03
- EW股票行情：愛德華生命科學的股票在週二下跌了0.2％，收於$ 63.64。
- Benzinga Pro的實時新聞提醒了最新的愛德華生命科學資訊。
DexCom Inc (NASDAQ:DXCM)
DexCom Inc（納斯達克：DXCM）
- On July 25, DexCom reported worse-than-expected second-quarter revenue results and issued weak revenue guidance. "While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," said Kevin Sayer, Dexcom's CEO. "We have a unique opportunity to serve millions of more customers around the world with our differentiated product portfolio and we are taking action to improve our execution and best position ourselves for continued long-term growth." The company's stock fell around 38% over the past five days. It has a 52-week low of $62.34.
- RSI Value: 20.25
- DXCM Price Action: Shares of DexCom gained 3.3% to close at $69.70 on Tuesday.
- Benzinga Pro's charting tool helped identify the trend in DXCM stock.
- 德康醫療於7月25日公佈了次季度營收低於預期及弱勢營收預測。德康醫療的首席執行官Kevin Sayer表示：「雖然德康在第二季度推進了幾項關鍵戰略舉措，但我們的執行並未達到高標準。我們有獨特的機會爲全球數百萬客戶提供差異化的產品組合，並採取行動改善我們的執行，以最佳姿態繼續實現長期增長。」公司的股票在過去5天下跌了近38%，並創下了52周內的最低價$ 62.34。
- RSI值：20.25
- DXCm股票行情：德康醫療的股票在週二上漲了3.3％，收於$ 69.70。
- Benzinga Pro的圖表工具幫助識別DXCm股票的趨勢。
Biomx Inc (NYSE:PHGE)
biomx Inc（紐交所：PHGE）。
- On July 29, BiomX announced NYSE American acceptance of plan to regain listing compliance. The company's stock dipped around 43% over the past month and has a 52-week low of $0.19.
- RSI Value: 24.28
- PHGE Price Action: Shares of Biomx fell 8.5% to close at $0.19 on Tuesday.
- Benzinga Pro's signals feature notified of a potential breakout in Biomx shares.
- BiomX於7月29日宣佈接受紐約證交所美國交易所的計劃以恢復上市資格。該公司的股價在過去一個月內下跌了近43%，並創下了52周內的最低價$ 0.19。
- RSI值：24.28。
- PHGE股票行情：Biomx的股票在週二下跌了8.5％，收於$ 0.19。
- Benzinga Pro的信號功能通知了Biomx股票潛在突破的可能性。
Read More:
閱讀更多：
- Nasdaq Tumbles As Microsoft, Nvidia And Other Tech Stocks Decline: Greed Index Moves To 'Fear' Zone
- 微軟、英偉達和其他科技股下跌，納斯達克指數下跌：貪婪指數降至“恐懼”區域
譯文內容由第三人軟體翻譯。